Kamolwish Laoprasopwattana, MD

Prince of Songkla University
Songkla, Pattani, Thailand

Disclosure(s): Merck & Co., Inc., Rahway, NJ, USA: Grant/Research Support, MSD - PI for this study

Presentation(s):

• 166 - A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants

  Thursday, October 17, 2024
  2:09 PM – 2:21 PM US PT